Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Defining actionable mutations for oncology therapeutic development.

Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC.

Nat Rev Cancer. 2016 Apr 26;16(5):319-29. doi: 10.1038/nrc.2016.35. Review.

PMID:
27112209
2.

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M.

Breast Cancer Res. 2015 Mar 11;17:35. doi: 10.1186/s13058-015-0532-0.

3.

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.

Ribas R, Ghazoui Z, Gao Q, Pancholi S, Rani A, Dunbier A, Dowsett M, Martin LA.

Breast Cancer Res. 2014 Oct 31;16(5):447. doi: 10.1186/s13058-014-0447-1.

4.

Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.

Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M.

Clin Cancer Res. 2014 Aug 1;20(15):3962-73. doi: 10.1158/1078-0432.CCR-13-1378. Epub 2014 Jun 10.

5.

Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response.

Gao Q, Patani N, Dunbier AK, Ghazoui Z, Zvelebil M, Martin LA, Dowsett M.

Clin Cancer Res. 2014 May 1;20(9):2485-94. doi: 10.1158/1078-0432.CCR-13-2602. Epub 2014 Mar 14.

6.

Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.

Lu Y, You M, Ghazoui Z, Liu P, Vedell PT, Wen W, Bode AM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2013 Nov;6(11):1151-61. doi: 10.1158/1940-6207.CAPR-13-0126. Epub 2013 Sep 25.

7.

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M.

Clin Cancer Res. 2013 May 15;19(10):2775-86. doi: 10.1158/1078-0432.CCR-12-1000. Epub 2013 Mar 14.

8.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.

9.
10.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL.

Cancer Discov. 2011 Sep;1(4):338-51. doi: 10.1158/2159-8290.CD-11-0101. Epub 2011 Jul 20.

11.

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, Skene T, Evans A, A'Hern R, Iskender A, Wilcox M, Bliss J.

J Natl Cancer Inst Monogr. 2011;2011(43):120-3. doi: 10.1093/jncimonographs/lgr034.

PMID:
22043057
12.

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K, Arbogast S, Johnston S, Dowsett M.

Endocr Relat Cancer. 2011 Aug 30;18(5):565-77. doi: 10.1530/ERC-10-0046. Print 2011 Oct.

PMID:
21734071
13.

ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.

Dunbier AK, Anderson H, Ghazoui Z, Lopez-Knowles E, Pancholi S, Ribas R, Drury S, Sidhu K, Leary A, Martin LA, Dowsett M.

PLoS Genet. 2011 Apr;7(4):e1001382. doi: 10.1371/journal.pgen.1001382. Epub 2011 Apr 28.

14.

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.

Martin LA, Ghazoui Z, Weigel MT, Pancholi S, Dunbier A, Johnston S, Dowsett M.

Steroids. 2011 Jul;76(8):772-6. doi: 10.1016/j.steroids.2011.02.035. Epub 2011 Apr 6.

PMID:
21477608
15.

Association between breast cancer subtypes and response to neoadjuvant anastrozole.

Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, Smith IE, Dowsett M.

Steroids. 2011 Jul;76(8):736-40. doi: 10.1016/j.steroids.2011.02.025. Epub 2011 Apr 5.

PMID:
21447351
16.

A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.

Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL.

Clin Cancer Res. 2011 Apr 1;17(7):2024-34. doi: 10.1158/1078-0432.CCR-10-2567. Epub 2011 Feb 23.

17.

Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.

Ghazoui Z, Buffa FM, Dunbier AK, Anderson H, Dexter T, Detre S, Salter J, Smith IE, Harris AL, Dowsett M.

Clin Cancer Res. 2011 May 1;17(9):3005-12. doi: 10.1158/1078-0432.CCR-10-1704. Epub 2011 Feb 15. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4915. Clin Cancer Res. 2011 May 1;17(9). doi:10.1158/1078-0432.CCR-11-1325.

18.

Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M.

J Clin Oncol. 2010 Mar 1;28(7):1161-7. doi: 10.1200/JCO.2009.23.9616. Epub 2010 Feb 1.

19.

A common genomic framework for a diverse assembly of plasmids in the symbiotic nitrogen fixing bacteria.

Crossman LC, Castillo-Ramírez S, McAnnula C, Lozano L, Vernikos GS, Acosta JL, Ghazoui ZF, Hernández-González I, Meakin G, Walker AW, Hynes MF, Young JP, Downie JA, Romero D, Johnston AW, Dávila G, Parkhill J, González V.

PLoS One. 2008 Jul 2;3(7):e2567. doi: 10.1371/journal.pone.0002567. Erratum in: PLoS ONE. 2008;3(8). doi: 10.1371/annotation/8d8e2649-c772-4363-b70b-b242c42f505f. PLoS ONE. 2008;3(8). doi: 10.1371/annotation/4a58a9bd-7531-41d0-b101-53039a88c25b.

20.

The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.

Banerjee S, Pancholi S, A'hern R, Ghazoui Z, Smith IE, Dowsett M, Martin LA.

Clin Cancer Res. 2008 May 1;14(9):2656-63. doi: 10.1158/1078-0432.CCR-07-1352.

21.

The genome of Rhizobium leguminosarum has recognizable core and accessory components.

Young JP, Crossman LC, Johnston AW, Thomson NR, Ghazoui ZF, Hull KH, Wexler M, Curson AR, Todd JD, Poole PS, Mauchline TH, East AK, Quail MA, Churcher C, Arrowsmith C, Cherevach I, Chillingworth T, Clarke K, Cronin A, Davis P, Fraser A, Hance Z, Hauser H, Jagels K, Moule S, Mungall K, Norbertczak H, Rabbinowitsch E, Sanders M, Simmonds M, Whitehead S, Parkhill J.

Genome Biol. 2006;7(4):R34. Epub 2006 Apr 26. Review.

Supplemental Content

Loading ...
Support Center